Corante

About this Author
Derek Lowe
Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: derekb.lowe@gmail.com Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Emolecules
ChemSpider
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
PubChem
Not Voodoo
DailyMed
Druglib
Clinicaltrials.gov

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
MedChem Buzz
Kilomentor
On Pharma
A New Merck, Reviewed
Liberal Arts Chemistry
One in Ten Thousand
Electron Pusher
Periodic Tabloid
All Things Metathesis
C&E News Blog
Propter Doc
Chemiotics II
The Chemical Notebook
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
Chirality
BBSRC/Douglas Kell
ChemBark
Drug Discovery Opinion
Realizations in Biostatistics
Chemjobber
Pharmalot
WSJ Health Blog
ChemSpider Blog
Pharmagossip
Med-Chemist
Organic Chem - Education & Industry
Useful Chemistry
Chiral Jones
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
SimBioSys
The Curious Wavefunction
Natural Product Man
Totally Synthetic
Fragment Literature
The F- Blog
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Carbon-Based Curiosities
Experimental Error
Business|Bytes|Genes|Molecules
Eye on FDA
Sigma-Aldrich ChemBlogs
Chemical Forums
Depth-First
Symyx Blog
P212121
ChemCafe
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa


Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
FuturePundit
Aetiology
Gene Expression (I)
Gene Expression (II)
Sciencebase
Pharyngula
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
A Scientist's Life
Speculist
Cosmic Variance
The Capsule
Zeroth Order Approximation
Biology News Net


Medical Blogs
Med Tech Sentinel
DB's Medical Rants
Science-Based Medicine
GruntDoc
The Health Care Blog
Respectful Insolence
Black Triangle
Diabetes Mine


Economics and Business
Marginal Revolution
Arnold Kling
The Volokh Conspiracy
Knowledge Problem
The Stalwart


Politics / Current Events
Virginia Postrel
Tinkerty Tonk
Instapundit
Megan McArdle
Mickey Kaus
Colby Cosh
Alien Corn
No Watermelons


Belles Lettres
Two Blowhards
Critical Mass
Arts and Letters Daily
God of the Machine
Armavirumque
About Last Night
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« Run It Past the Chemists | Main | Lilly's R&D Outsourcing »

January 5, 2010

Always Read the Fine Print

Email This Entry

Posted by Derek

. . .especially when you're dealing with the Swiss. You'll have probably seen that Novartis is buying Alcon. But what price they're buying them at depends on who you are.

As the Wall Street Journal reports, Novartis, who already had 25% of Alcon's stock, is paying majority shareholder Nestlé $180/share for their 52% stake in the company. Minority shareholders - that is, all the rest of them - are being offered $153. Some of these folks have paid up over $160/share recently, anticipating such a deal, but under Swiss law, there's not a thing that they can do about it. . .

Comments (6) + TrackBacks (0) | Category: Business and Markets


COMMENTS

1. TexMex on January 5, 2010 2:53 PM writes...

I wondered if anyone knows how many people will be let go as a result of this. How much of the research will be outsourced? Any Rumours?

Permalink to Comment

2. Sili on January 5, 2010 3:12 PM writes...

Is this just a matter of Swiss law? What makes this deal illegal elsewhere?

Aren't we all free to buy and sell what we want/have at our own price?

Permalink to Comment

3. Palo on January 5, 2010 3:55 PM writes...

Paying a premium for majority control of Alcon makes sense. And with that acquisition Novartis has more than 75% of the company... why would they offer the other shareholders more than the stock was valued at a month ago? (And why do we need to start mistrusting the swiss?)

Permalink to Comment

4. Lucifer on January 6, 2010 1:33 AM writes...

Ok.. here is my much-delayed blog. Any suggestions on topics and directions are welcome.

http://pharmaheretic.wordpress.com/

I already have a popular and much more politically incorrect blog + science is more than skewering imbeciles. Therefore I will post once or twice a week, instead of everyday like at my other blog.

Permalink to Comment

5. Hap on January 6, 2010 10:14 AM writes...

You can offer me $153 for my stock, but in most places I can tell you where (in which orifice) to place your offer. Are the minority stockholders required to sell, because if not, I'm pretty sure I know how much of my stock they'd be getting at that price (well, if I actually had any). The only other question would be whether you think the company will get worse, in which case, $153 is better than $90, or $0.

Permalink to Comment

6. canuck on January 8, 2010 2:47 PM writes...

this explains it some more....
http://dealbook.blogs.nytimes.com/2010/01/06/the-alcon-independent-directors-dilemma

Permalink to Comment

POST A COMMENT




Remember Me?



EMAIL THIS ENTRY TO A FRIEND

Email this entry to:

Your email address:

Message (optional):




RELATED ENTRIES
PhDs On Food Stamps?
Laboratory Crime, Not Paying
Buckyball Longevity: The Lead Author Replies
More Details
You're A Peer, Too, You Know
The CETP Saga Continues (And It's Not Getting More Entertaining)
Cytotoxic? You Bet!
Benlysta's Adventures In the Real World